Clinical Trial News and Research

RSS

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

By the time bone cancer is diagnosed in a pet dog, it is often too late to save the animal's life. Instead, the goal of treatment is to keep the dog as comfortable and free of pain as possible for as long as possible.

25 Oct 2013

Transcatheter Technologies reports first-in-human implantation of transapical TRINITY aortic valve

Transcatheter Technologies GmbH, a emerging medical device company that is developing a next-generation transcatheter aortic heart valve prosthesis, announced today the successful first-in-human implantation of its transapical TRINITY aortic valve designed to be the world's best repositionable heart valve.

25 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

Merck provides overview of clinical trial program for HPV vaccine V503

Merck, known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the company's investigational 9-valent human papillomavirus vaccine, to the Advisory Committee on Immunization Practices in the United States.

25 Oct 2013

MEDIAN Technologies announces participation in World Conference on Lung Cancer

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, today announced its participation in the World Conference on Lung Cancer, to be held October 27-30, in Sydney, Australia.

24 Oct 2013

New imaging tool could someday be used for routine breast cancer screenings

Breast cancer is one of the most common forms of cancer and cancer deaths among women worldwide. Routine screening can increase breast cancer survival by detecting the disease early and allowing doctors to address it at this critical stage.

23 Oct 2013

Tissue-engineered transplants safe and effective in the long term: Study

New results published in The Lancet today [Wednesday 23 October] reveal that five years after the first successful transplantation of a tissue-engineered airway (reported in The Lancet in 2008) the recipient continues to enjoy a good quality of life, and has not experienced any immunological complications or rejection of the implanted airway.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Flu vaccine may also reduce risk of heart attack by 50% among people who had heart attack

The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.

23 Oct 2013

Clinical trial to investigate if vitamin D supplement helps prevent type 2 diabetes

Researchers have begun the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay type 2 diabetes in adults who have prediabetes, who are at high risk for developing type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States.

23 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

Researchers report that in patients with pseudocysts with viscous debris-laden fluid, endoscopic ultrasound-guided drainage by using a combination of a nasocystic drain and transmural stents improves clinical outcomes and lowers the stent occlusion rate compared with those who underwent drainage via stents alone.

22 Oct 2013

Clinical trial to determine whether vitamin D helps prevent or delay development of type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 to 200 adults to take part in the local arm of a major national clinical trial that will investigate whether vitamin D helps prevent or delay development of type 2 diabetes.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published online in the journal Stroke.

22 Oct 2013

Clinical Trial News and Research

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

Transcatheter Technologies reports first-in-human implantation of transapical TRINITY aortic valve

Study finds persistent deficiency in new therapeutics for neglected diseases

Merck provides overview of clinical trial program for HPV vaccine V503

MEDIAN Technologies announces participation in World Conference on Lung Cancer

New imaging tool could someday be used for routine breast cancer screenings

Tissue-engineered transplants safe and effective in the long term: Study

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Flu vaccine may also reduce risk of heart attack by 50% among people who had heart attack

Clinical trial to investigate if vitamin D supplement helps prevent type 2 diabetes

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

COPD treatments: an interview with Professor Price, University of Aberdeen

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

Clinical trial to determine whether vitamin D helps prevent or delay development of type 2 diabetes

Clinical trials will help to develop treatment and follow-up of COPD patients

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer